Skip to content
WorldBrand.AI

CStone Pharmaceuticals

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2022

    CStone's over 50 million yuan investment paper loss and executive exits spark controversy

    CStone Pharmaceuticals disclosed a paper loss of about 54.81 million yuan on wealth management investments; during the same period, its vice president of finance left and founder Jiang Ningjun stepped down as chairman of the board. The company was suspended from trading for a time, triggering investor doubts about its fund management. The company adjusted its management.

    Source